Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
Basilea (SIX: BSLN) bags another milestone payment
Published by Arron Aatkar

Basilea has received a US$25m milestone payment from Pfizer, its license partner in Europe, triggered by the strong sales performance of lead antifungal asset Cresemba in this region. Multiple milestone payments have been announced this year for exceeding sales thresholds in the Asia-Pacific region and China, reflecting the sustained market traction for Cresemba across the globe, and further significant milestones are anticipated in H224. According to management, total global in-market sales of Cresemba amounted to US$489m in the 12 months between April 2023 and March 2024, representing 24% growth year-on-year.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free